BCEL Atreca Inc.

9.78
0  0%
Previous Close 9.78
Open 9.89
52 Week Low 9.6
52 Week High 25.03
Market Cap $360,793,687
Shares 36,890,970
Float 22,378,500
Enterprise Value $143,953,996
Volume 219,919
Av. Daily Volume 238,926
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ATRC-101
Solid tumors
Phase 1b
Phase 1b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. REDWOOD CITY, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    20th Annual Needham Virtual Healthcare Conference
    Tuesday, April 13, 2021
    Presentation time: 1:30 p.m. EDT

    Canaccord Genuity Horizons in Oncology Virtual Conference
    Thursday, April 15, 2021
    Panel time: 4:00 p.m. EDT

    A live audio webcast of the Needham presentation can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. An archived replay will…

    REDWOOD CITY, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    20th Annual Needham Virtual Healthcare Conference

    Tuesday, April 13, 2021

    Presentation time: 1:30 p.m. EDT

    Canaccord Genuity Horizons in Oncology Virtual Conference

    Thursday, April 15, 2021

    Panel time: 4:00 p.m. EDT

    A live audio webcast of the Needham presentation can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. An archived replay will be available on the company's website for 90 days following the live presentation.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Certain statements in this press release regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans and the timing thereof, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, the activity of ATRC-101 or potential future candidates once administered in human subjects, and the implementation of our strategic plans for our business, technologies, and current or potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the U.S. Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and subsequent filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390

     

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a trial-in-progress poster will be presented at the virtual AACR Annual Meeting, which is being held over two one-week periods: April 10 – 15 and May 17 – 21 2021. The poster will describe the design of the company's ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 as monotherapy and in combination with pembrolizumab in patients with solid tumor cancers.

    Details of the presentation are as follows:

    Title: First-in-human…

    SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a trial-in-progress poster will be presented at the virtual AACR Annual Meeting, which is being held over two one-week periods: April 10 – 15 and May 17 – 21 2021. The poster will describe the design of the company's ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 as monotherapy and in combination with pembrolizumab in patients with solid tumor cancers.

    Details of the presentation are as follows:

    Title: First-in-human phase 1b study of ATRC-101, a patient-derived antibody with a tumor-specific target, as monotherapy or in combination with pembrolizumab, in patients with solid tumors

    Session Title: Phase I Clinical Trials in Progress

    Abstract Number: CT203

    Full text of abstract will be released on the AACR website at 12:01 a.m. EDT on Friday, April 9 and the poster will be made available on the company's website once the virtual program begins on Saturday, April 10.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Certain statements in this press release regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans and the timing thereof, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, the activity of ATRC-101 or potential future candidates once administered in human subjects, and the implementation of our strategic plans for our business, technologies, and current or potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the U.S. Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and subsequent filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390

     

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent developments.

    "2020 was a successful year for Atreca marked by several key milestones, including the initiation of our first-in-human study of ATRC-101 and the signing of multiple strategic collaborations to both enhance our discovery platform and build our development pipeline," said John Orwin, Chief Executive Officer. "Preclinical…

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent developments.

    "2020 was a successful year for Atreca marked by several key milestones, including the initiation of our first-in-human study of ATRC-101 and the signing of multiple strategic collaborations to both enhance our discovery platform and build our development pipeline," said John Orwin, Chief Executive Officer. "Preclinical data that we presented on ATRC-101 throughout the year highlighted its novel target and mechanism of action, as well as its potential as a combination therapy both with checkpoint inhibitors targeting the PD-1/PD-L1 axis and with chemotherapy. This year we look forward to reporting initial summary data from our Phase 1b trial, initiating combination studies with a checkpoint inhibitor and chemotherapy, and providing an update on our early-stage pipeline."

    Recent Developments and Highlights

    • To date, 10 clinical trial sites have been initiated in the Phase 1b trial evaluating ATRC-101 in multiple solid tumor cancers. Three patients have been enrolled in the fourth dose cohort (10mg/kg) of the dose escalation portion of the trial. Patient enrollment in the fifth and final dose cohort (30mg/kg) is planned to begin following the protocol-specified dose-limiting toxicity assessment period. Atreca expects to announce initial summary data from the study in 2Q 2021.

    • As allowed by the study protocol, up to three additional patients are being backfilled into the previously cleared third dose cohort (3mg/kg) due to continued interest in the study and in order to collect supplemental data. The dose expansion portion of the study is also being opened with an additional 3mg/kg cohort expected to enroll up to 12 patients. Further cohorts to evaluate ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic agent are planned to begin in 2Q 2021 and 2H 2021, respectively.

    Fourth Quarter and Full Year 2020 Financial Results

    • As of December 31, 2020, cash and cash equivalents and short-term investments totaled $240.1 million.



    • Research and development expenses for the year ended December 31, 2020 were $62.0 million, including non-cash share-based compensation expense of $5.9 million. Research and development expenses for the three months ended December 31, 2020 were $16.8 million, including non-cash share-based compensation expense of $1.4 million.



    • General and administrative expenses for the year ended December 31, 2020 were $26.8 million, including non-cash share-based compensation expense of $6.6 million. General and administrative expenses for the three months ended December 31, 2020 were $6.6 million, including non-cash share-based compensation expense of $1.7 million.



    • Atreca reported a net loss of $86.3 million, or basic and diluted net loss per share attributable to common stockholders of $2.70, for the year ended December 31, 2020. The Company reported a net loss of $23.0 million, or basic and diluted net loss per share attributable to common stockholders of $0.63, for the three months ended December 31, 2020.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Certain statements in this press release regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans and the timing thereof, and the progress of our discovery platform and development efforts with our existing and potential future collaboration and research arrangements, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, the activity of ATRC-101 or potential future candidates once administered in human subjects, and the implementation of our strategic plans for our business, technologies, and current or potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.



    Atreca, Inc. 
    Condensed Consolidated Balance Sheets 
    (in thousands, except share and per share data) 
          
      December 31,

     December 31, 
      2020 2019 
          
    ASSETS     
          
    Current Assets
    Cash and cash equivalents $60,789  $157,954  
    Investments  179,296   14,663  
    Prepaid expenses and other current assets  9,037   3,502  
    Total current assets  249,122   176,119  
    Property and equipment, net  19,831   5,771  
    Long-term investments  -   10,799  
    Deposits and other  3,111   3,026  
    Total assets $272,064  $195,715  
          
    LIABILITIES AND STOCKHOLDERS' EQUITY
          
    Current Liabilities
    Accounts payable $5,216  $2,133  
    Accrued expenses  10,302   5,395  
    Other current liabilities  1,900   419  
    Total current liabilities  17,418   7,947  
    Capital lease obligations, net of current portion  4   53  
    Deferred rent  12,585   763  
    Total liabilities  30,007   8,763  
          
          
    Stockholders' equity
    Common stock  4   3  
    Additional paid-in capital  492,436   351,039  
    Accumulated other comprehensive income  58   16  
    Accumulated deficit  (250,441)  (164,106) 
    Total stockholders' equity  242,057   186,952  
    Total liabilities and stockholders' equity $272,064  $195,715  
          

     

    Atreca, Inc.
    Condensed Consolidated Statements of Operations
    (in thousands, except share and per share data)
              
       Three Months Ended Year Ended
       December 31, December 31,
        2020  2019  2020  2019
            
       (unaudited)    
    Expenses        
     Research and development $16,847  $14,279  $62,045  $54,726 
     General and administrative  6,639   6,926   26,834   17,845 
     Total expenses  23,486   21,205   88,879   72,571 
    Interest and other income (expense)        
     Other income  366   329   1,353   2,134 
     Interest income  136   885   1,218   3,213 
     Interest expense  (1)  (1)  (4)  (6)
     Preferred stock warrant liability revaluation   —    —    —   (123)
     Foreign exchange loss   —   (7)   —   (8)
     Loss on disposal of property and equipment  (22)  (115)  (22)  (122)
    Loss before Income tax expense  (23,007)  (20,114)  (86,334)  (67,483)
    Income tax expense  -   1   (1)  (1)
    Net loss $(23,007) $(20,113) $(86,335) $(67,484)
    Net loss per share, basic and diluted $(0.63) $(0.72) $(2.70) $(4.26)
    Weighted-average shares used in computing        
    net loss per share, basic and diluted  36,726,441   27,959,975   31,924,473   15,834,175 
              

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390

    Source: Atreca, Inc.

     

     



    Primary Logo

    View Full Article Hide Full Article
  4. SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    Cowen 41st Annual Health Care Conference
    Date: Monday, March 1, 2021
    Panel discussion time: 1:20 p.m. EST
    Title: "Novel Oncology Targets"

    H.C. Wainwright Global Life Sciences Conference
    Date: Tuesday, March 9, 2021
    Presentation time: 7:00 a.m. EST

    33rd Annual Roth Conference
    Date: Tuesday, March 16, 2021
    Fireside chat time: 4:00 p.m. EDT

    A live audio webcast of the H.C…

    SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    Cowen 41st Annual Health Care Conference

    Date: Monday, March 1, 2021

    Panel discussion time: 1:20 p.m. EST

    Title: "Novel Oncology Targets"

    H.C. Wainwright Global Life Sciences Conference

    Date: Tuesday, March 9, 2021

    Presentation time: 7:00 a.m. EST

    33rd Annual Roth Conference

    Date: Tuesday, March 16, 2021

    Fireside chat time: 4:00 p.m. EDT

    A live audio webcast of the H.C. Wainwright and Roth presentations can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of both presentations will be available on the Company's website for 90 days following the live event.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  5. SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments.

    "We continued to make progress enrolling patients and activating trial sites in our Phase 1b trial of ATRC-101 during the third quarter and anticipate reporting initial summary data in the first half of 2021," said John Orwin, Chief Executive Officer. "We recently presented preclinical data at SITC 2020 further highlighting the…

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments.

    "We continued to make progress enrolling patients and activating trial sites in our Phase 1b trial of ATRC-101 during the third quarter and anticipate reporting initial summary data in the first half of 2021," said John Orwin, Chief Executive Officer. "We recently presented preclinical data at SITC 2020 further highlighting the potential for ATRC-101 as a combination therapy with checkpoint inhibitors targeting the PD-1/PD-L1 axis. We expect to initiate combination studies with a checkpoint inhibitor as well as with chemotherapy, and to commence monotherapy expansion cohorts, in 2021."

    Recent Developments and Highlights

    • Screening in the Phase 1b first-in-human study evaluating ATRC-101 in patients with select solid tumor cancers is ongoing, and patients are currently being enrolled in the third dose cohort. To date, seven clinical trial sites have been activated, including two additional sites in the third quarter of 2020, and Atreca expects to announce initial summary data from the study in the first half of 2021. In addition to monotherapy expansion cohorts, clinical trials of ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic are planned for 2021.



    • Atreca presented two posters describing preclinical evaluations of ATRC-101 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020). The presentations provide insight into the cooperation between checkpoint inhibitors targeting the PD-1/PD-L1 axis and ATRC-101 as well as the potent single-agent activity of ATRC-101 in syngeneic mouse tumor models. Both posters are currently available on Atreca's website.

    Third Quarter 2020 Financial Results

    • As of September 30, 2020, cash, cash equivalents and investments totaled $259.5 million.



    • Research and development expenses for the three months ended September 30, 2020 were $16.8 million, including non-cash share-based compensation expense of $1.6 million.



    • General and administrative expenses for the three months ended September 30, 2020 were $6.6 million, including non-cash share-based compensation expense of $1.9 million.



    • Atreca reported a net loss of $22.9 million, or basic and diluted net loss per share attributable to common stockholders of $0.66, for the three months ended September 30, 2020.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

     
     
    Atreca, Inc.
    Condensed Consolidated Balance Sheets
    (in thousands, except share and per share data)
         
      September 30,December 31, 
       2020   2019 
         
    ASSETS    
         
    Current Assets
    Cash and cash equivalents $133,072  $157,954 
    Investments  126,192   14,663 
    Prepaid expenses and other current assets  4,898   3,502 
    Total current assets  264,162   176,119 
    Property and equipment, net  7,783   5,771 
    Long-term investments  205   10,799 
    Deposits and other  3,043   3,026 
    Total assets $275,193  $195,715 
         
    LIABILITIES AND STOCKHOLDERS' EQUITY
         
    Current Liabilities
    Accounts payable $2,524  $2,133 
    Accrued expenses  5,309   5,395 
    Other current liabilities  1,442   419 
    Total current liabilities  9,275   7,947 
    Capital lease obligations, net of current portion  17   53 
    Deferred rent  4,621   763 
    Total liabilities  13,913   8,763 
         
         
    Stockholders' equity
    Common stock  4   3 
    Additional paid-in capital  488,593   351,039 
    Accumulated other comprehensive income  117   16 
    Accumulated deficit  (227,434)  (164,106)
    Total stockholders' equity  261,280   186,952 
    Total liabilities and stockholders' equity $275,193  $195,715 
         





     
    Atreca, Inc.
    Condensed Consolidated Statements of Operations
    (in thousands, except share and per share data)
           (unaudited)
              
       Three Months Ended Nine Months Ended
       September 30, September 30,
        2020   2019   2020   2019 
    Expenses        
     Research and development $16,808  $12,812  $45,198  $40,447 
     General and administrative  6,614   4,864   20,195   10,919 
     Total expenses  23,422   17,676   65,393   51,366 
    Interest and other income (expense)        
     Other income  353   619   987   1,805 
     Interest income  142   1,189   1,082   2,328 
     Interest expense  (1)  (1)  (3)  (5)
     Preferred stock warrant liability revaluation           (123)
     Foreign exchange loss     (1)     (1)
     Loss on disposal of property and equipment           (7)
    Loss before Income tax expense  (22,928)  (15,870)  (63,327)  (47,369)
    Income tax expense  (1)  (1)  (1)  (2)
    Net loss $(22,929) $(15,871) $(63,328) $(47,371)
    Net loss per share, basic and diluted $(0.66) $(0.57) $(2.09) $(4.03)
    Weighted-average shares used in computing        
    net loss per share, basic and diluted  34,723,888   27,949,682   30,313,047   11,747,825 
              



    Contacts


    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251, ext. 251

    Media:

    Sheryl Seapy, 213-262-9390

     

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
View All Atreca Inc. News